The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise

References

• Andersen KW, Mouridsen HT. Danish Breast Cancer Cooperative Group (DBCG). A description of the register of the nation-wide programme for primary breast cancer. Acta Oncol 1988; 27: 627–47
   PubMed Web of Science ®Google Scholar
• Blichert-Toft M, Christiansen P, Mouridsen HT. Danish Breast Cancer Cooperative Group – DBCG: History, organisation, and status of scientific achievements at 30-year anniversary. Acta Oncol 2008; 47: 497–505
   PubMed Web of Science ®Google Scholar
• Mouridsen HT, Bjerre KD, Christiansen P, Jensen M-B, Møller S. Improvement of prognosis in breast cancer in Denmark –2006, based on the nationwide reporting to the DBCG registry. Acta Oncol ;47 1977; 2008: 525–36
   Google Scholar
• Kier HV, Nielsen BB, Bjerre KD, Lænkholm AV. Classical pathological variables recorded in the Danish Breast Cancer Cooperative Group's register –2006. Acta Oncol ;47 1978; 2008: 778–83
   Google Scholar
• Blichert-Toft M, Nielsen M, Düring M, Møller S, Rank F, Overgaard M, et al. Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol. Acta Oncol 2008; 47: 672–81
   PubMed Web of Science ®Google Scholar
• Christiansen P, Friis E, Balslev E, Jensen D, Møller S. Sentinel node biopsy in breast cancer: Five years experience from Denmark. Acta Oncol 2008; 47: 561–68
   PubMed Web of Science ®Google Scholar
• Juul Christensen J, Overgaard M. Postoperative radiotherapy in DBCG during 30 years. Development of techniques, evaluation of indications and clinical radiobiological perspectives. Acta Oncol 2008; 47: 639–53
   PubMed Web of Science ®Google Scholar
• Nielsen HM, Overgaard J, Grau C, Christensen JJ, Overgaard M. Audit of the radiotherapy in the DBCG 82 b&c trials--a validation study of the 1,538 patients randomised to postmastectomy radiotherapy. Radiother Oncol 2005; 76: 285–92
   PubMed Web of Science ®Google Scholar
• Thomsen MS, Berg M, Nielsen HM, Pedersen AN, Overgaard M, Ewertz M, et al. Post-mastectomy radiotherapy in Denmark: From 2D to 3D treastment planning guidelines of The Danish Breast Cancer Cooperative Group. Acta Oncol 2008; 47: 654–61
   PubMed Web of Science ®Google Scholar
• Brincker H, Mouridsen HT, Andersen KW, Andersen J, Castberg T, Fisherman K, et al. Increased breast-cancer recurrence rate after adjuvant therapy with lavamisole. Lancet 1980; 2: 824–7
   PubMed Web of Science ®Google Scholar
• Dombernowsky P, Brincker H, Hansen M, Mouridsen HT, Overgaard M, Panduro J, et al. Adjuvant therapy of premenopausal and menopausal high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group Trials 77-B and 82-B. Acta Oncol 1988; 27: 691–7
   PubMed Web of Science ®Google Scholar
• Mouridsen HT, Rose C, Overgaard M, Dombernowsky P, Panduro J, Thorpe S, et al. Adjuvant treatment of postmenopausal patients with high-risk primary breast cancer. Results from the Danish adjuvant trials. DBCG 77 C and DBCG 82 C. Acta Oncol 1988; 27: 699–705
   PubMed Web of Science ®Google Scholar
• Overgaard, M, Hansen, PS, Overgaard, J, Rose, C, Andersson, M, Bach, F, for the Danish Breast Cancer Cooperative Group 82b Trial, et al. Postoperative radiotherapy in high-risk pre-menopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 1997;337:945–55.
   Web of Science ®Google Scholar
• Overgaard M, Jensen M-B, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999; 353: 1641–48
   PubMed Web of Science ®Google Scholar
• Højris I, Overgaard M, Christensen JJ, Overgaard J. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: Analysis of DBCG 82b and 82c randomised trials. Lancet 1999; 354: 1425–30
   PubMed Web of Science ®Google Scholar
• Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 2007; 82: 247–53
   PubMed Web of Science ®Google Scholar
• Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: Long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol 2006; 24: 2268–75
   PubMed Web of Science ®Google Scholar
• Andersson M, Kamby C, Jensen MB, Mouridsen H, Ejlertsen B, Dombernowsky P, et al. Tamoxifen in high-risk pre-menopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer Co-Operative Group DBCG 82B trial. Eur J Cancer 1999; 35: 1659–66
   PubMed Web of Science ®Google Scholar
• Ejlertsen B, Mouridsen HT, Jensen MB, Bengtsson NO, Bergh J, Cold S, et al. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: From a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. J Clin Oncol 2006; 24: 4956–62
   PubMed Web of Science ®Google Scholar
• Andersen J, Kamby C, Ejlertsen B, Cold S, Ewertz M, Jacobsen EH, et al. Similar efficacy of tamoxifen for one year versus two years versus 6 month of tamoxifen followed by 6 month of megestrol acetate: Results from a randomized comparison in postmenopausal high-risk patients with hormone receptor positive or unknown breast cancer (DBCG trial 89C). Acta Oncol 2008; 47: 718–24
   PubMed Web of Science ®Google Scholar
• Ejlertsen B, Mouridsen HT, Jensen M-B, Andersen J, Jensen BB, Cold S, et al. Improved outcome from substituting methotrexate with epirubicin: Results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. Eur J Cancer 2007; 43: 877–84
   PubMed Web of Science ®Google Scholar
• Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, et al. Retrospective analysis of Topoiso-merase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate and fluorouracil or cyclophosphamide, epirubicin and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005; 23: 7483–90
   PubMed Web of Science ®Google Scholar
• Kristensen B, Ejlertsen B, Mouridsen HT, Jensen M-B, Andersen J, Bjerregaard B, et al. Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 2008; 47: 740–46
   PubMed Web of Science ®Google Scholar
• Thürlimann B, Keshaviah A, Coates AS, Mouridsen HT, Mauriac L, Forbes JF, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 350: 2747–57
   Google Scholar
• Coombes RC, Hall E, Gibson LJ, Paridaens R., Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081–92
   PubMed Web of Science ®Google Scholar
• Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M, et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst 2008; 100: 121–33
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Traztuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659–72
   PubMed Web of Science ®Google Scholar
• Lænkholm A-V, Jensen M-B, Kroman N, Rank F. Breast cancer in situ. From pre-malignant lesion of uncertain significance to well-defined non-invasive malignant lesion. The Danish Breast Cancer Cooperative Group –2007 revisited. Acta Oncol ;47 1977; 2008: 765–71
   Google Scholar
• Thomassen T, Hansen TO, Borg A, Lianee HT, Wikman F, Pedersen IS, et al. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer. Acta Oncol 2008; 47: 772–77
   PubMed Web of Science ®Google Scholar
• Rostgaard K, Holst H, Mouridsen HT, Lynge E. Do clinical databases render population-based cancer registers obsolete. The example of breast cancer in Denmark. Cancer Causes Control 2000; 11: 669–74
   PubMed Web of Science ®Google Scholar
• Jensen AJ, Storm HH, Møller S, Overgaard J. Validity and Representativity in the Danish Breast Cancer Cooperative Group. Acta Oncol 2003; 42: 179–85
   PubMed Web of Science ®Google Scholar
• Hansen PS, Andersen E, Andersen KW, Mouridsen HT. quality control of end results in a danish adjuvant breast cancer multi-center study. Acta Oncol 1997; 36: 711–4
   PubMed Web of Science ®Google Scholar
• Christensen, P , Al-Suliman , Bjerre, KD , Møller, S . Low-risk breast cancer – Follow-up from the DBCG 89-A program. Acta Oncol 2008;47:691–703.
   PubMed Web of Science ®Google Scholar
• August DA, Thomas R, Sondak VK. Age-related differences in breast cancer treatment. Ann Surg Oncol 1994; 1: 45–52
   PubMed Web of Science ®Google Scholar
• Ballard-Barbash R, Potosky AL, Harlan LC, Nayfield SG, Kessler LG. Factors associated with surgical and radiation therapy for early stage breast cancer in older women. J Natl Cancer Inst 1996; 88: 716–26
   PubMed Web of Science ®Google Scholar
• Tyldesley S, Zhang-Salomons J, Groome PA, Zhou S, Schulze K, Paszat LF, et al. Association between age and the utilization of radiotherapy in Ontario. Int J Radiat Oncol Biol Phys 2000; 47: 469–80
   PubMed Web of Science ®Google Scholar
• Kemeny M, Peterson BL, Kornblith AB, Muss HB, Wheeler J, Levine E, et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 2003; 21: 2268–75
   PubMed Web of Science ®Google Scholar